Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 52,592 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Pushkal Garg also recently made the following trade(s):

• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Trading Down 1.9 %

Shares of ALNY opened at $273.99 on Thursday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a market capitalization of $35.34 billion, a price-to-earnings ratio of -104.58 and a beta of 0.34. The company has a 50-day moving average of $249.42 and a 200 day moving average of $260.65. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same period last year, the firm earned $1.15 EPS. On average, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current year.

Wall Street Analysts Forecast Growth

ALNY has been the subject of a number of research analyst reports. Barclays lifted their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. TD Cowen raised their target price on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Piper Sandler restated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Wolfe Research cut Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Finally, StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $298.61.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of ALNY. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth approximately $61,160,000. Strategic Financial Concepts LLC bought a new position in shares of Alnylam Pharmaceuticals in the 4th quarter worth $41,529,000. Eventide Asset Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 157.9% during the 3rd quarter. Eventide Asset Management LLC now owns 224,333 shares of the biopharmaceutical company’s stock worth $61,698,000 after purchasing an additional 137,333 shares during the last quarter. Los Angeles Capital Management LLC boosted its position in Alnylam Pharmaceuticals by 11,433.4% during the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after purchasing an additional 135,829 shares in the last quarter. Finally, Telemark Asset Management LLC purchased a new position in Alnylam Pharmaceuticals in the third quarter valued at about $27,503,000. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.